Peptide Catalog

A small-molecule NNMT inhibitor (technically not a peptide) grouped with peptides in fat-loss contexts, investigated in preclinical obesity and muscle-aging models.

A 16-amino-acid fragment of the C-terminus of human growth hormone (residues 176–191), marketed for fat-loss lipolytic activity but weak in controlled human trials.

A topical hexapeptide marketed as a 'topical Botox' — mimics a SNAP-25 fragment to dampen neurotransmitter release at the dermal-epidermal junction.

A 15-amino-acid peptide fragment derived from gastric juice protein BPC, studied extensively in animal models for tissue healing and gut integrity.

The most widely used GHRH + GHRP stack — CJC-1295 extends GHRH half-life while Ipamorelin selectively amplifies GH pulses without disturbing cortisol or prolactin.

Enzymatically hydrolyzed collagen broken into short peptides that survive digestion — marketed for skin, joint, and connective-tissue support.

A 9-amino-acid neuropeptide isolated from the rabbit brain, investigated for delta-wave sleep promotion and stress-axis modulation.

A synthetic tetrapeptide (Ala-Glu-Asp-Gly) modeled on pineal extract Epithalamin — studied by Russian researchers for telomerase, circadian, and longevity endpoints.

A naturally occurring copper-binding tripeptide (Gly-His-Lys) with decades of cosmetic dermatology research in wound healing and skin remodeling.

An early-generation growth-hormone-releasing peptide with potent GHSR agonism but notable prolactin elevation compared to the later selective agent Ipamorelin.

The first-generation growth-hormone-releasing peptide, notable for inducing strong hunger through ghrelin-receptor activation alongside GH release.

A potent GHRP with documented cardioprotective effects in ischemic animal models, distinct from other GHRPs in its non-GH receptor activity.

A long-acting analog of insulin-like growth factor 1 with substitutions that reduce IGF-binding-protein affinity, extending half-life and increasing free IGF-1 activity.

The most selective GHRP (growth-hormone-releasing peptide) — amplifies GH pulses via ghrelin/GHSR receptor without meaningful cortisol, prolactin, or aldosterone crosstalk.

The first GLP-1 receptor agonist approved for chronic weight management (Saxenda, 2014) — an acylated human GLP-1 analog with ~13-hour half-life dosed once daily.

Fish-derived hydrolyzed collagen — smaller molecular weight than bovine, often claimed to have superior bioavailability though head-to-head evidence is limited.

A well-studied topical peptide combination marketed for wrinkle reduction — the palmitoyl lipid tail enables penetration past the stratum corneum.

A synthetic analog of α-MSH that binds melanocortin receptors, inducing melanogenesis (tanning) along with libido and appetite-suppression effects. Pre-PT-141 ancestor molecule.

A 16-amino-acid peptide encoded in the mitochondrial 12S rRNA — investigated as a metabolic regulator of AMPK signaling and insulin sensitivity.

A melanocortin receptor agonist FDA-approved for hypoactive sexual desire disorder in premenopausal women, acting on central nervous-system pathways rather than vascular ones.

An investigational triple GIP / GLP-1 / glucagon receptor agonist from Eli Lilly, showing the largest weight-loss effect sizes yet reported in obesity trials (up to ~24% at 48 weeks in phase-2).

A synthetic heptapeptide analog of tuftsin, developed at the Russian Institute of Molecular Genetics as an anxiolytic nootropic administered intranasally.

Long-acting GLP-1 receptor agonist — FDA-approved for type-2 diabetes and chronic weight management, landmark for its ~15% mean weight reduction in STEP trials.

A synthetic heptapeptide fragment of ACTH (4-10) developed in Russia as a cognitive enhancer, used clinically there for stroke recovery and anxiety.

The first synthetic GHRH analog approved for clinical use — GHRH (1-29) NH₂, the minimum active sequence. Shorter-acting than tesamorelin or CJC-1295.

An MC4R-selective melanocortin agonist FDA-approved for rare genetic obesity syndromes (POMC, PCSK1, LEPR deficiency, Bardet-Biedl syndrome).

Synthetic fragment of Thymosin β4 investigated for actin-binding, cell migration, and tissue repair across muscle, cornea, and cardiac models.

FDA-approved synthetic GHRH analog indicated for HIV-associated lipodystrophy, studied for visceral adipose tissue reduction and cognitive endpoints.

A 28-amino-acid thymic peptide approved in 30+ countries (not US) for hepatitis B/C and as an immune adjunct in oncology and infectious disease.

First-in-class dual GIP/GLP-1 receptor agonist — SURMOUNT trials showed ~20% mean weight reduction and superior A1c control versus semaglutide.